Like most ride-hailing companies, Didi had historically been unprofitable, until it reported a profit of US$30 million in the first quarter of this year. Liu Zhen, the head of Uber China at the time, is Didi’s Liu’s cousin. The company counts SoftBank, Uber Technologies Inc and Tencent as its main backers.ĭidi is also known for successfully pushing Uber out of the Chinese market after the US company lost a price war and ended up selling its China operations to Didi for a stake. Cheng was joined by Jean Qing Liu, a former Goldman banker and the current president of the ride-sharing company. The book is covered multiple times by investors, two sources told Reuters yesterday.Īn over-allotment option, or greenshoe, exists where a further 43.2 million shares can be sold to increase the size of the deal.ĭidi was co-founded in 2012 by former Alibaba employee Will Wei Cheng, who currently serves as the chief executive officer. investors will not get access to Chinese IPOs for quite some time.Didi’s IPO was covered early on the first day of the book-build last week and the investor books were closed on Monday, one day ahead of schedule. In other words, it seems like a good bet that U.S. Interestingly enough, even if this is not the case, there will likely be lots of skepticism for new deals. If anything, the Chinese government may ultimately not want domestic companies to tap foreign markets for capital. It is also far from clear when things may normalize. There will likely be more delays and withdrawals of Chinese IPOs. Regulatory authorities banned the downloading of the app, sparking a 19% selloff in the shares. Already we’ve seen how this has adversely impacted the recent public offering for Didi Chuxing ( DIDI), which is China’s leading ride-sharing company. The Communist government has taken more forceful actions against tech companies, especially those focused on using personal data. Note that some of the best tech operators, like IBM, have struggled with applying AI to healthcare.Īlthough, it has actually been regulatory changes in China that have been the biggest risk for LinkDoc. Even though the company has a data advantage, the fact is that finding the causes and treatments for oncological diseases is extremely complicated and subject to stringent regulatory requirements. LinkDoc is still in the early stages and there is considerable risk with the technology. What’s more, the market for oncology big data went from $500 million in 2015 to $2.1 billion in 2019 and is forecasted to reach $119.6 billion by 2030. Regarding oncology, it has the highest growth rate for the patient pool. Consider that China has the world’s second largest healthcare market and the spending is expected to increase at close to 10% per year until 2030, reaching $2.529 trillion. Yet the market opportunity is substantial. During the latest quarter, the revenues jumped by 41% to $34.1 million. This not only has provided for next-generation treatments but has allowed for a rich source of data collection.Īs for the growth rate, it has been robust. These systems also interact with each other, such as with data integration.Īnother key to the strategy is a nationwide network of 34 patient care centers. There is LinkCare for continuous care for disease, LinkData for AI-based curation based on longitudinal medical data and LinkSolutions for helping life science companies accelerate drug development. The company has three different offerings. According to research from Frost & Sullien, LinkDoc has the largest dataset of China’s oncology cohorts and has built the most extensive digital infrastructure for precision medicine. Perhaps the most important is its trove of valuable data.
Nevertheless, LinkDoc has some major advantages.
0 kommentar(er)
